FK506-binding protein 12–Calcineurin complex (FKBP12–CaN complex)

The FK506-binding protein 12 (FKBP12)–Calcineurin complex is a ternary molecular assembly that plays a pivotal role in the suppression of the adaptive immune system. It is formed when the macrolide immunosuppressant Tacrolimus (FK506) binds to the cytosolic immunophilin FKBP12; this binary complex then gains a high affinity for Calcineurin, a calcium-calmodulin-dependent serine/threonine phosphatase (StatPearls, 2023). In a healthy immune response, Calcineurin dephosphorylates the Nuclear Factor of Activated T-cells (NFAT), enabling its translocation into the nucleus to induce the expression of Interleukin-2 (IL-2) and other pro-inflammatory cytokines (PubMed, PMID: 11403362). By sterically hindering the active site of Calcineurin, the FKBP12–Tacrolimus complex prevents NFAT activation, thereby inhibiting T-cell proliferation and cytokine production. This target is primarily exploited to prevent allograft rejection in organ transplant recipients and to treat severe autoimmune or inflammatory conditions like atopic dermatitis (NIH, PubChem). However, because Calcineurin is expressed in various tissues, including the kidneys and brain, pharmacological modulation of this complex is associated with significant side effects such as nephrotoxicity and neurotoxicity. Therapeutic drug monitoring of Tacrolimus levels is essential to balance efficacy with these safety concerns.

Other names

FKBP12-FK506-calcineurin complexFKBP1A-PPP3CA-PPP3R1 complexFKBP12-PP2B complexFK506-binding protein 1A–Calcineurin complex

Tacrolimus binds to FKBP12 to form a drug-protein complex that inhibits the phosphatase activity of calcineurin, preventing the dephosphorylation and nuclear translocation of NFAT (Nuclear Factor of Activated T-cells).